Besifloxacin

Drug Profile

Besifloxacin

Alternative Names: Besifloxacin ophthalmic suspension 0.6%; Besivance; BOL-303224-A; ISV-403; Optura; SS 734

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator InSite Vision; SSP Co
  • Developer Bausch & Lomb; Rutgers
  • Class Antibacterials; Azepines; Carboxylic acids; Cyclopropanes; Fluoroquinolones; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Infectious conjunctivitis
  • No development reported Eye disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Eye-disorders(In infants) in USA (Ophthalmic, Suspension)
  • 03 Nov 2015 InSite Vision became an indirect wholly owned subsidiary of Sun Pharma
  • 04 Feb 2015 Launched for Infectious conjunctivitis in Argentina, Singapore, Hong Kong and Malaysia (Ophthalmic) before February 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top